REG - BSF Enterprise PLC - Interim Financial Statements

BSF EnterpriseAnnouncement

29/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220629:nRSc5055Qa&default-theme=true

RNS Number : 5055Q  BSF Enterprise PLC  29 June 2022

29 June 2022

BSF Enterprise PLC

Interim Financial Statements

The Board of BSF Enterprise PLC is pleased to announce its Unaudited Interim
Financial Statements for the six months ended 31 March 2022, which are
available on the Company's website: www.bsfenterprise.com
(http://www.bsfenterprise.com) .

As required under Listing Rule 9.6.1 R, these have been submitted to the
National Storage Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:

 BSF Enterprise PLC                        Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Graham Duncan - Chief Financial Officer

 Shard Capital (Broker)
 Damon Heath                               020 7186 9952

 Erik Woolgar

 SEC Newgate (Financial Communications)
 Bob Huxford                               020 3757 6882

 Elisabeth Cowell                          BSF@secnewgate.co.uk

 George Esmond

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DOCBXGDLGGDDGDI